Comparison of peroral endoscopic cardial constriction and double-dose esomeprazole on clinical efficacy of refractory gastroesophageal reflux disease

doi:10.3877/cma.j.issn.2095-7157.2021.04.005

Abstract

Abstract:

Objective

To compare the clinical efficacy of peroral endoscopic cardial constriction (PECC) and double-dose esomeprazole on the treatment of refractory gastroesophageal reflux disease (rGERD).

Methods

A prospective randomized controlled study was conducted on the data of 64 patients with rGERD at Baoding No.1 Central Hospital from January 2019 to May 2020. According to the principle of randomized control trial, patients were divided into PECC group and esomeprazole group, with 32 cases in each group.The former under went PECC and the latter taken oral esomeprazole and mosapride citrate. The reflux symptoms, quality of life scores and satisfaction between the two groups were compared after 3 and 6 months.

Results

After 3 and 6 months follow-up reflux disease questionnaire (RDQ), reflux symptom index (RSI), health related quality of life scale gastroesophageal reflux disease (GERD-HRQL) scores in the PECC group were significantly lower than those in the esomeprazole group (P<0.01). After 6 months follow-up, the satisfaction rate of PECC group and esomeprazole group was 87.5% (28/32) and 40.63% (13/32), respectively.There was significant difference in satisfaction between the two groups (P<0.05), and no obvious serious complications in the PECC group.

Conclusion

In terms of short-term efficacy, PECC is more advantageous than double-dose esomeprazole in improving reflux symptoms and enhancing quality of life in patients with rGERD. It can alleviate the symptoms of rGERD throat reflux, and significantly reduce rGERD acid reflux、heartburn and other esophageal reflux symptoms. It can distinctly improve the quality of life and can be used as a treatment option for rGERD.

Key words: Peroral endoscopic cardial constriction, Esomeprazole, Refractory gastroesophageal reflux disease, Relieve symptoms, Satisfaction

Huixia Cao, Ying Xiong, Jing Han, Jinzhuo Zhang, Yichao Yang, Yaling Wang, Chongyang Yang. Comparison of peroral endoscopic cardial constriction and double-dose esomeprazole on clinical efficacy of refractory gastroesophageal reflux disease[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2021, 08(04): 171-175.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2021.04.005

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2021/V08/I04/171

Figures/Tables 3

References 16

[1]	Eusebi LH, Ratnakumaran R, Yuan Y，et al. Global prevalence of, and risk factors for，gastro-oesophageal reflux symptoms：a meta-analysis[J]. Gut，2018，67(3)：430-440.
[2]	Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease[J]. BMJ，2020，371：m3786.
[3]	Delshad SD, Almario CV, Chey WD，et al.Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms[J]. Gastroenterology，2020，158(5)：1250-1261.
[4]	中华医学会消化病学分会.2020年中国胃食管反流病专家共识[J]．中华消化杂志，2020，40(10)：649-663.
[5]	Li ZT, Ji F, Han XW, et al. Endoscopic cardial constriction with band ligation in the treatment of refractory gastroesophageal reflux disease: a preliminary feasibility study[J]. Surg Endosc，2021，35(7)：4035-4041.
[6]	胡海清，柴宁莉，令狐恩强，等. 经口内镜下贲门缩窄术治疗胃食管反流病的临床研究[J/CD]．中华胃肠内镜电子杂志，2016，3(2)：65-67.
[7]	令狐恩强，王宇菲，王潇潇．经口内镜下贲门缩窄术治疗胃食管反流病的报道一例[J/CD]．中华腔镜外科杂志(电子版)，2013，6(6)：468-469.
[8]	唐小波，王亚雷，许建明．胃食管反流病问卷在胃食管反流病诊断中的价值[J]．安徽医科大学学报，2011，46(3)：275-278.
[9]	Akbulut S, Aydinli FE, Kuşçu O，et al. Reliability and Validity of the Turkish Reflux Symptom Index[J]. J Voice，2020，34(6)：965. e23-965. e28.
[10]	Ionova TI, Nikitina TP, Mayevskaya EA，et al. Development of the Russian version of quality of life questionnaire in patients with GERD-GERD-HRQL[J]. Ter Arkh，2020，92(8)：12-17.
[11]	El-Serag H, Becher A, Jones R. Systematic review：persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies[J]. Aliment Pharmacol Ther，2010，32(6)：720-737.
[12]	Hillman L, Yadlapati R, Thuluvath AJ，et al. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease[J]. Dis Esophagus，2017，30(9)：1-15.
[13]	Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of gastroesophageal reflux disease：Where rome，Lyon，and Montreal Meet[J]. Clin Gastroenterol Hepatol，2020，18(4)：767-776.
[14]	Gyawali CP, Kahrilas PJ, Savarino E，et al. Modern diagnosis of GERD: the Lyon Consensus[J]. Gut，2018，67(7)：1351-1362.
[15]	Lee JY, Kim SK, Cho KB, et al. A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease[J]. J Neurogastroenterol Motil，2017，23(2)：218-228.
[16]	Bai Y, Du Y, Zou D，et al. Gastroesophageal Reflux Disease Questionnaire(GerdQ)in real-world practice：a national multicenter survey on 8065 patients[J]. J Gastroenterol Hepatol，2013，28(4): 626-631.

组别	例数	性别[例(男/女)]	年龄[岁(±s)]	病程[年(±s)]	洛杉矶分型(例，A/B/C)
PECC组	32	18/14	51.72±13.35	4.31±1.28	11/15/6
艾司奥美拉唑组	32	15/17	52.56±12.06	3.88±1.18	12/13/7
χ²/t值		0.25	0.27	-1.42	0.58
P值		0.61	0.79	0.16	0.75

组别	例数	性别[例(男/女)]	年龄[岁(±s)]	病程[年(±s)]	洛杉矶分型(例，A/B/C)
PECC组	32	18/14	51.72±13.35	4.31±1.28	11/15/6
艾司奥美拉唑组	32	15/17	52.56±12.06	3.88±1.18	12/13/7
χ²/t值		0.25	0.27	-1.42	0.58
P值		0.61	0.79	0.16	0.75

组别	RDQ/分			RSI/分			GERD-HRQL/分
组别	治疗前	治疗3个月后	治疗6个月后	治疗前	治疗3个月后	治疗6个月后	治疗前	治疗3个月后	治疗6个月后
PECC组	17.91±3.95	3.25±2.00	3.59±1.74	9.69±3.76	2.84±1.19	3.63±1.24	20.69±6.91	2.91±1.33	4.34±1.38
艾司奥美拉唑组	18.09±4.07	12.13±6.13	14.53±5.47	9.21±4.30	5.97±2.98	7.13±3.09	22.13±8.03	9.81±4.11	13.75±3.67
t值	0.19	7.78	10.79	-0.46	5.51	5.95	0.77	9.05	13.57
P值	0.85	<0.01	<0.01	0.64	<0.01	<0.01	0.45	<0.01	<0.01

组别	RDQ/分			RSI/分			GERD-HRQL/分
组别	治疗前	治疗3个月后	治疗6个月后	治疗前	治疗3个月后	治疗6个月后	治疗前	治疗3个月后	治疗6个月后
PECC组	17.91±3.95	3.25±2.00	3.59±1.74	9.69±3.76	2.84±1.19	3.63±1.24	20.69±6.91	2.91±1.33	4.34±1.38
艾司奥美拉唑组	18.09±4.07	12.13±6.13	14.53±5.47	9.21±4.30	5.97±2.98	7.13±3.09	22.13±8.03	9.81±4.11	13.75±3.67
t值	0.19	7.78	10.79	-0.46	5.51	5.95	0.77	9.05	13.57
P值	0.85	<0.01	<0.01	0.64	<0.01	<0.01	0.45	<0.01	<0.01

Please choose a citation manager

Content to export